Oral sulfonylureas for the treatment of type II diabetes: an update
- PMID: 3082015
- DOI: 10.1097/00007611-198603000-00019
Oral sulfonylureas for the treatment of type II diabetes: an update
Abstract
Oral hypoglycemic agents have been in clinical use since 1956 in the United States. Two new second-generation sulfonylureas, glipizide and glyburide, have been marketed recently. This article reviews the pharmacology of the oral sulfonylureas, compares the drugs from a safety and efficacy standpoint, and provides updated information regarding their use in the management of type II non-insulin-dependent diabetes mellitus.